Lub Yim Hli21,Cov tshuaj epcoritamab, uas yog ib yam tshuaj uas siv los kho cov kab mob B cell malignancies, tau txais kev tshuaj xyuas ua ntej los ntawm Lub Chaw Saib Xyuas Tshuaj (CDE) ntawm Lub Chaw Tswj Xyuas Khoom Siv Kho Mob Hauv Tebchaws (NMPA). Kev pom zoo no yog rau cov neeg mob laus uas muaj mob follicular lymphoma (FL) uas rov qab mob dua lossis tsis kho tau, uas yog ib pawg tshuaj uas xav tau ntau ntawm cov kab mob B cell malignancies.
Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Txog Epcoritamab
Epcoritamab yog ib qho IgG1-bispecific antibody tsim los ntawm kev siv Genmab's proprietary DuoBody technology thiab muab tshuaj rau hauv qab daim tawv nqaij. Genmab's DuoBody-CD3 technology yog tsim los coj cov cytotoxic T cell xaiv los ua kom muaj kev tiv thaiv kab mob rau cov hom cell. Epcoritamab yog tsim los khi rau CD3 ntawm T cell thiab CD20 ntawm B cell tib lub sijhawm thiab ua rau T-cell-mediated tua CD20+ cell.
Txog Follicular Lymphoma (FL)
FL feem ntau yog ib hom mob non-Hodgkin's lymphoma (NHL) uas tsis loj hlob sai (lossis loj hlob qeeb) uas tshwm sim los ntawm B-lymphocytes thiab yog hom mob NHL thib ob uas pom ntau tshaj plaws, suav txog 20-30 feem pua ntawm tag nrho cov neeg mob.i Kwv yees li 15,000 tus neeg mob FL txhua xyoo hauv Tebchaws Meskasii thiab nws suav tias tsis kho tau nrog cov kev kho mob niaj hnub no.ii Cov neeg mob feem ntau rov qab mob dua thiab, txhua zaus rov qab mob dua, qhov kev zam txim thiab lub sijhawm mus rau kev kho mob tom ntej luv dua.iv Dhau sijhawm, kev hloov pauv mus rau diffuse large B-cell lymphoma (DLBCL), ib hom mob NHL uas cuam tshuam nrog cov txiaj ntsig tsis zoo ntawm kev ciaj sia, tuaj yeem tshwm sim rau ntau dua 25 feem pua ntawm cov neeg mob FL.
EPCORE FL-1 (NCT05409066) yog ib qho kev sim tshuaj qhib theem 3 los ntsuam xyuas qhov kev nyab xeeb thiab kev ua tau zoo ntawm epcoritamab ntxiv rau rituximab thiab lenalidomide (R2) piv rau R2 ib leeg rau cov neeg mob uas rov qab mob/tsis khov kho (R/R) follicular lymphoma (FL).
Lub Yim Hli 7,Genmab A/Stshaj tawm cov txiaj ntsig zoo ntawm Theem 3 EPCORE FL-1 kev sim tshuaj ntsuam xyuas subcutaneous epcoritamab, ib qho bispecific antibody, ua ke nrog rituximab thiab lenalidomide (R®2) piv rau R2 ib leeg rau kev kho mob rau cov neeg laus uas muaj relapsed lossis refractory (R/R) follicular lymphoma (FL). Txoj kev tshawb fawb no tau ntsib nws ob qho kawg tseem ceeb ntawm kev teb tag nrho (ORR, p-value < 0.0001) thiab kev ciaj sia tsis muaj kev nce qib (PFS, HR 0.21, p-value < 0.0001), qhia txog qhov sib txawv tseem ceeb thiab kev kho mob hauv ob qho kawg, txo qhov kev pheej hmoo ntawm kev nce qib lossis kev tuag los ntawm 79%.
Tam sim no, tseem muaj ntau qhov kev sim tshuaj kho mob qog noj ntshav tshiab hauv Suav teb nrhiav cov neeg mob. Kev sab laj txog cov tshuaj tshiab thiab cov thev naus laus zis, koj tuaj yeem tiv tauj Beijing South Region Oncology Hospital International Department.
Xov Tooj: 4008803716
WeChat ID: 17801183037
Email：myimmnet@163.com
Lub sijhawm tshaj tawm: Cuaj hlis-05-2025